Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

Rebecca Feldman, PhD
Published: Friday, Oct 09, 2015



Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which could potentially have an oncogenic role in breast cancer.

In a recent study, researchers sought to determine whether caveolin-1 (CAV1) is a tumor suppressor or a proto-oncogene in patients with breast cancer. Due to known interactions with signaling molecules, it was investigated whether or not CAV1-positive breast cancers differ from CAV1-negative breast cancers.

CAV1 positivity was found to be significantly associated with triple-negative breast cancer (TNBC) status, which coincided with earlier studies. A further analysis examined patients with CAV1-positive TNBC versus CAV1-negative TNBC. EGFR was found to be upregulated in patients with CAV1-positivity by protein expression. Additionally, overexpression of PDGFRA, ERCC1, and TLE3 were also found in CAV1-positive patients.



Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which could potentially have an oncogenic role in breast cancer.

In a recent study, researchers sought to determine whether caveolin-1 (CAV1) is a tumor suppressor or a proto-oncogene in patients with breast cancer. Due to known interactions with signaling molecules, it was investigated whether or not CAV1-positive breast cancers differ from CAV1-negative breast cancers.

CAV1 positivity was found to be significantly associated with triple-negative breast cancer (TNBC) status, which coincided with earlier studies. A further analysis examined patients with CAV1-positive TNBC versus CAV1-negative TNBC. EGFR was found to be upregulated in patients with CAV1-positivity by protein expression. Additionally, overexpression of PDGFRA, ERCC1, and TLE3 were also found in CAV1-positive patients.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x